Matija Peterlin, MD

CFAR Mentees


  1. Bartholomeeusen K, Xiang Y, Fujinaga K, Peterlin BM. Bromodomain and Extra-terminal (BET) Bromodomain Inhibition Activate Transcription via Transient Release of Positive Transcription Elongation Factor b (P-TEFb) from 7SK Small Nuclear Ribonucleoprotein. J Biol Chem. 2012 Oct 19; 287(43):36609-16.
  2. Fujinaga K, Barboric M, Li Q, Luo Z, Price DH, Peterlin BM. PKC phosphorylates HEXIM1 and regulates P-TEFb activity. Nucleic Acids Res. 2012 Oct; 40(18):9160-70.
  3. Lu C, Luo Z, Jäger S, Krogan NJ, Peterlin BM. Moloney leukemia virus type 10 inhibits reverse transcription and retrotransposition of intracisternal a particles. J Virol. 2012 Oct; 86(19):10517-23.
  4. Zumer K, Low AK, Jiang H, Saksela K, Peterlin BM. Unmodified Histone H3K4 and DNA-Dependent Protein Kinase Recruit Autoimmune Regulator to Target Genes. Mol Cell Biol. 2012 Apr; 32(8):1354-62.
  5. Peterlin BM, Brogie JE, Price DH. 7SK snRNA: a noncoding RNA that plays a major role in regulating eukaryotic transcription. Wiley Interdiscip Rev RNA. 2012 Jan; 3(1):92-103.
  6. Peterlin BM. Transcription elongation takes central stage: the P-TEFb connection. Cell Cycle. 2010 Aug 1; 9(15):2933-4.
  7. Lenassi M, Cagney G, Liao M, Vaupotic T, Bartholomeeusen K, Cheng Y, Krogan NJ, Plemenitas A, Peterlin BM. HIV Nef is secreted in exosomes and triggers apoptosis in bystander CD4+ T cells. Traffic. 2010 Jan; 11(1):110-22.
  8. Chen H, Contreras X, Yamaguchi Y, Handa H, Peterlin BM, Guo S. Repression of RNA polymerase II elongation in vivo is critically dependent on the C-terminus of Spt5. PLoS One. 2009; 4(9):e6918.
  9. Li Q, Peterlin BM. Genetic analysis of P-TEFb function via heterologous nucleic acid tethering systems. Methods. 2009 Aug; 48(4):375-80.
  10. Barboric M, Lenasi T, Chen H, Johansen EB, Guo S, Peterlin BM. 7SK snRNP/P-TEFb couples transcription elongation with alternative splicing and is essential for vertebrate development. Proc Natl Acad Sci U S A. 2009 May 12; 106(19):7798-803.
  11. Contreras X, Schweneker M, Chen CS, McCune JM, Deeks SG, Martin J, Peterlin BM. Suberoylanilide hydroxamic acid reactivates HIV from latently infected cells. J Biol Chem. 2009 Mar 13; 284(11):6782-9.
  12. Lenasi T, Contreras X, Peterlin BM. Transcriptional interference antagonizes proviral gene expression to promote HIV latency. Cell Host Microbe. 2008 Aug 14; 4(2):123-33.
  13. Su MA, Giang K, Zumer K, Jiang H, Oven I, Rinn JL, Devoss JJ, Johannes KP, Lu W, Gardner J, Chang A, Bubulya P, Chang HY, Peterlin BM, Anderson MS. Mechanisms of an autoimmunity syndrome in mice caused by a dominant mutation in Aire. J Clin Invest. 2008 May; 118(5):1712-26.
  14. Blazek D, Peterlin BM. Tat-SIRT1 tango. Mol Cell. 2008 Mar 14; 29(5):539-40.
  15. Aguiar RS, Peterlin BM. APOBEC3 proteins and reverse transcription. Virus Res. 2008 Jun; 134(1-2):74-85.
  16. Aguiar RS, Lovsin N, Tanuri A, Peterlin BM. Vpr.A3A chimera inhibits HIV replication. J Biol Chem. 2008 Feb 1; 283(5):2518-25.
  17. Jiang H, Peterlin BM. Differential chromatin looping regulates CD4 expression in immature thymocytes. Mol Cell Biol. 2008 Feb; 28(3):907-12.
  18. Oven I, Brdicková N, Kohoutek J, Vaupotic T, Narat M, Peterlin BM. AIRE recruits P-TEFb for transcriptional elongation of target genes in medullary thymic epithelial cells. Mol Cell Biol. 2007 Dec; 27(24):8815-23.
  19. Contreras X, Barboric M, Lenasi T, Peterlin BM. HMBA releases P-TEFb from HEXIM1 and 7SK snRNA via PI3K/Akt and activates HIV transcription. PLoS Pathog. 2007 Oct 12; 3(10):1459-69.
  20. Drozina G, Kohoutek J, Nishiya T, Peterlin BM. Sequential modifications in class II transactivator isoform 1 induced by lipopolysaccharide stimulate major histocompatibility complex class II transcription in macrophages. J Biol Chem. 2006 Dec 29; 281(52):39963-70.
  21. Kohoutek J, Blazek D, Peterlin BM. Hexim1 sequesters positive transcription elongation factor b from the class II transactivator on MHC class II promoters. Proc Natl Acad Sci U S A. 2006 Nov 14; 103(46):17349-54.
  22. Peterlin BM, Price DH. Controlling the elongation phase of transcription with P-TEFb. Mol Cell. 2006 Aug 4; 23(3):297-305.
  23. Lenasi T, Peterlin BM, Dovc P. Distal regulation of alternative splicing by splicing enhancer in equine beta-casein intron 1. RNA. 2006 Mar; 12(3):498-507.
  24. Blazek D, Barboric M, Kohoutek J, Oven I, Peterlin BM. Oligomerization of HEXIM1 via 7SK snRNA and coiled-coil region directs the inhibition of P-TEFb. Nucleic Acids Res. 2005; 33(22):7000-10.
  25. Barboric M, Kohoutek J, Price JP, Blazek D, Price DH, Peterlin BM. Interplay between 7SK snRNA and oppositely charged regions in HEXIM1 direct the inhibition of P-TEFb. EMBO J. 2005 Dec 21; 24(24):4291-303.
  26. Jiang H, Zhang F, Kurosu T, Peterlin BM. Runx1 binds positive transcription elongation factor b and represses transcriptional elongation by RNA polymerase II: possible mechanism of CD4 silencing. Mol Cell Biol. 2005 Dec; 25(24):10675-83.
  27. Barboric M, Zhang F, Besenicar M, Plemenitas A, Peterlin BM. Ubiquitylation of Cdk9 by Skp2 facilitates optimal Tat transactivation. J Virol. 2005 Sep; 79(17):11135-41.
  28. Zheng YH, Peterlin BM. Intracellular immunity to HIV-1: newly defined retroviral battles inside infected cells. Retrovirology. 2005; 2:25.
  29. Barboric M, Peterlin BM. A new paradigm in eukaryotic biology: HIV Tat and the control of transcriptional elongation. PLoS Biol. 2005 Feb; 3(2):e76.
  30. Zheng YH, Lovsin N, Peterlin BM. Newly identified host factors modulate HIV replication. Immunol Lett. 2005 Mar 15; 97(2):225-34.
  31. Drozina G, Kohoutek J, Jabrane-Ferrat N, Peterlin BM. Expression of MHC II genes. Curr Top Microbiol Immunol. 2005; 290:147-70.
  32. Kurosu T, Zhang F, Peterlin BM. Transcriptional activity and substrate recognition of cyclin T2 from P-TEFb. Gene. 2004 Dec 8; 343(1):173-9.
  33. Kurosu T, Peterlin BM. VP16 and ubiquitin; binding of P-TEFb via its activation domain and ubiquitin facilitates elongation of transcription of target genes. Curr Biol. 2004 Jun 22; 14(12):1112-6.
  34. Zheng YH, Irwin D, Kurosu T, Tokunaga K, Sata T, Peterlin BM. Human APOBEC3F is another host factor that blocks human immunodeficiency virus type 1 replication. J Virol. 2004 Jun; 78(11):6073-6.
  35. Costa LJ, Zheng YH, Sabotic J, Mak J, Fackler OT, Peterlin BM. Nef binds p6* in GagPol during replication of human immunodeficiency virus type 1. J Virol. 2004 May; 78(10):5311-23.
  36. Fujinaga K, Irwin D, Huang Y, Taube R, Kurosu T, Peterlin BM. Dynamics of human immunodeficiency virus transcription: P-TEFb phosphorylates RD and dissociates negative effectors from the transactivation response element. Mol Cell Biol. 2004 Jan; 24(2):787-95.
  37. Kanazawa S, Soucek L, Evan G, Okamoto T, Peterlin BM. c-Myc recruits P-TEFb for transcription, cellular proliferation and apoptosis. Oncogene. 2003 Aug 28; 22(36):5707-11.
  38. Lin X, Irwin D, Kanazawa S, Huang L, Romeo J, Yen TS, Peterlin BM. Transcriptional profiles of latent human immunodeficiency virus in infected individuals: effects of Tat on the host and reservoir. J Virol. 2003 Aug; 77(15):8227-36.
  39. Uematsu K, Kanazawa S, You L, He B, Xu Z, Li K, Peterlin BM, McCormick F, Jablons DM. Wnt pathway activation in mesothelioma: evidence of Dishevelled overexpression and transcriptional activity of beta-catenin. Cancer Res. 2003 Aug 1; 63(15):4547-51.
  40. Zheng YH, Yu HF, Peterlin BM. Human p32 protein relieves a post-transcriptional block to HIV replication in murine cells. Nat Cell Biol. 2003 Jul; 5(7):611-8.
  41. Zheng YH, Plemenitas A, Fielding CJ, Peterlin BM. Nef increases the synthesis of and transports cholesterol to lipid rafts and HIV-1 progeny virions. Proc Natl Acad Sci U S A. 2003 Jul 8; 100(14):8460-5.
  42. Jabrane-Ferrat N, Nekrep N, Tosi G, Esserman L, Peterlin BM. MHC class II enhanceosome: how is the class II transactivator recruited to DNA-bound activators? Int Immunol. 2003 Apr; 15(4):467-75.
  43. Zhang F, Barboric M, Blackwell TK, Peterlin BM. A model of repression: CTD analogs and PIE-1 inhibit transcriptional elongation by P-TEFb. Genes Dev. 2003 Mar 15; 17(6):748-58.
  44. Peterlin BM, Trono D. Hide, shield and strike back: how HIV-infected cells avoid immune eradication. Nat Rev Immunol. 2003 Feb; 3(2):97-107.
  45. Fujinaga K, Irwin D, Taube R, Zhang F, Geyer M, Peterlin BM. A minimal chimera of human cyclin T1 and tat binds TAR and activates human immunodeficiency virus transcription in murine cells. J Virol. 2002 Dec; 76(24):12934-9.
  46. Fujinaga K, Irwin D, Geyer M, Peterlin BM. Optimized chimeras between kinase-inactive mutant Cdk9 and truncated cyclin T1 proteins efficiently inhibit Tat transactivation and human immunodeficiency virus gene expression. J Virol. 2002 Nov; 76(21):10873-81.
  47. Tosi G, Jabrane-Ferrat N, Peterlin BM. Phosphorylation of CIITA directs its oligomerization, accumulation and increased activity on MHCII promoters. EMBO J. 2002 Oct 15; 21(20):5467-76.
  48. Nekrep N, Jabrane-Ferrat N, Wolf HM, Eibl MM, Geyer M, Peterlin BM. Mutation in a winged-helix DNA-binding motif causes atypical bare lymphocyte syndrome. Nat Immunol. 2002 Nov; 3(11):1075-81.
  49. Jabrane-Ferrat N, Nekrep N, Tosi G, Esserman LJ, Peterlin BM. Major histocompatibility complex class II transcriptional platform: assembly of nuclear factor Y and regulatory factor X (RFX) on DNA requires RFX5 dimers. Mol Cell Biol. 2002 Aug; 22(15):5616-25.
  50. Greene WC, Peterlin BM. Charting HIV's remarkable voyage through the cell: Basic science as a passport to future therapy. Nat Med. 2002 Jul; 8(7):673-80.
  51. Geyer M, Fackler OT, Peterlin BM. Subunit H of the V-ATPase involved in endocytosis shows homology to beta-adaptins. Mol Biol Cell. 2002 Jun; 13(6):2045-56.
  52. Geyer M, Yu H, Mandic R, Linnemann T, Zheng YH, Fackler OT, Peterlin BM. Subunit H of the V-ATPase binds to the medium chain of adaptor protein complex 2 and connects Nef to the endocytic machinery. J Biol Chem. 2002 Aug 9; 277(32):28521-9.
  53. Linnemann T, Zheng YH, Mandic R, Peterlin BM. Interaction between Nef and phosphatidylinositol-3-kinase leads to activation of p21-activated kinase and increased production of HIV. Virology. 2002 Mar 15; 294(2):246-55.
  54. Lin X, Taube R, Fujinaga K, Peterlin BM. P-TEFb containing cyclin K and Cdk9 can activate transcription via RNA. J Biol Chem. 2002 May 10; 277(19):16873-8.
  55. Lind KE, Du Z, Fujinaga K, Peterlin BM, James TL. Structure-based computational database screening, in vitro assay, and NMR assessment of compounds that target TAR RNA. Chem Biol. 2002 Feb; 9(2):185-93.
  56. Taube R, Lin X, Irwin D, Fujinaga K, Peterlin BM. Interaction between P-TEFb and the C-terminal domain of RNA polymerase II activates transcriptional elongation from sites upstream or downstream of target genes. Mol Cell Biol. 2002 Jan; 22(1):321-31.
  57. Barboric M, Nissen RM, Kanazawa S, Jabrane-Ferrat N, Peterlin BM. NF-kappaB binds P-TEFb to stimulate transcriptional elongation by RNA polymerase II. Mol Cell. 2001 Aug; 8(2):327-37.
  58. Nekrep N, Geyer M, Jabrane-Ferrat N, Peterlin BM. Analysis of ankyrin repeats reveals how a single point mutation in RFXANK results in bare lymphocyte syndrome. Mol Cell Biol. 2001 Aug; 21(16):5566-76.
  59. Fackler OT, d'Aloja P, Baur AS, Federico M, Peterlin BM. Nef from human immunodeficiency virus type 1(F12) inhibits viral production and infectivity. J Virol. 2001 Jul; 75(14):6601-8.
  60. Kanazawa S, Peterlin BM. Combinations of dominant-negative class II transactivator, p300 or CDK9 proteins block the expression of MHC II genes. Int Immunol. 2001 Jul; 13(7):951-8.
  61. Geyer M, Fackler OT, Peterlin BM. Structure--function relationships in HIV-1 Nef. EMBO Rep. 2001 Jul; 2(7):580-5.
  62. Zheng YH, Plemenitas A, Linnemann T, Fackler OT, Peterlin BM. Nef increases infectivity of HIV via lipid rafts. Curr Biol. 2001 Jun 5; 11(11):875-9.
  63. Geyer M, Peterlin BM. Domain assembly, surface accessibility and sequence conservation in full length HIV-1 Nef. FEBS Lett. 2001 May 11; 496(2-3):91-5.
  64. Fackler OT, Peterlin BM, Weis K. Lessons from HIV: movement of macromolecules inside the cell. Curr Mol Med. 2001 Mar; 1(1):1-7.
  65. Mandic R, Fackler OT, Geyer M, Linnemann T, Zheng YH, Peterlin BM. Negative factor from SIV binds to the catalytic subunit of the V-ATPase to internalize CD4 and to increase viral infectivity. Mol Biol Cell. 2001 Feb; 12(2):463-73.
  66. Fackler OT, Peterlin BM. Endocytic entry of HIV-1. Curr Biol. 2000 Aug 24; 10(16):1005-8.
  67. Barboric M, Taube R, Nekrep N, Fujinaga K, Peterlin BM. Binding of Tat to TAR and recruitment of positive transcription elongation factor b occur independently in bovine immunodeficiency virus. J Virol. 2000 Jul; 74(13):6039-44.
  68. Nekrep N, Jabrane-Ferrat N, Peterlin BM. Mutations in the bare lymphocyte syndrome define critical steps in the assembly of the regulatory factor X complex. Mol Cell Biol. 2000 Jun; 20(12):4455-61.
  69. Taube R, Fujinaga K, Irwin D, Wimmer J, Geyer M, Peterlin BM. Interactions between equine cyclin T1, Tat, and TAR are disrupted by a leucine-to-valine substitution found in human cyclin T1. J Virol. 2000 Jan; 74(2):892-8.
  70. Kanazawa S, Okamoto T, Peterlin BM. Tat competes with CIITA for the binding to P-TEFb and blocks the expression of MHC class II genes in HIV infection. Immunity. 2000 Jan; 12(1):61-70.
  71. Taube R, Fujinaga K, Wimmer J, Barboric M, Peterlin BM. Tat transactivation: a model for the regulation of eukaryotic transcriptional elongation. Virology. 1999 Nov 25; 264(2):245-53.
  72. Fontes JD, Kanazawa S, Nekrep N, Peterlin BM. The class II transactivator CIITA is a transcriptional integrator. Microbes Infect. 1999 Sep; 1(11):863-9.
  73. Fackler OT, Luo W, Geyer M, Alberts AS, Peterlin BM. Activation of Vav by Nef induces cytoskeletal rearrangements and downstream effector functions. Mol Cell. 1999 Jun; 3(6):729-39.
  74. Wimmer J, Fujinaga K, Taube R, Cujec TP, Zhu Y, Peng J, Price DH, Peterlin BM. Interactions between Tat and TAR and human immunodeficiency virus replication are facilitated by human cyclin T1 but not cyclins T2a or T2b. Virology. 1999 Mar 1; 255(1):182-9.
  75. Fujinaga K, Taube R, Wimmer J, Cujec TP, Peterlin BM. Interactions between human cyclin T, Tat, and the transactivation response element (TAR) are disrupted by a cysteine to tyrosine substitution found in mouse cyclin T. Proc Natl Acad Sci U S A. 1999 Feb 16; 96(4):1285-90.
  76. Fontes JD, Kanazawa S, Jean D, Peterlin BM. Interactions between the class II transactivator and CREB binding protein increase transcription of major histocompatibility complex class II genes. Mol Cell Biol. 1999 Jan; 19(1):941-7.
  77. Fujinaga K, Cujec TP, Peng J, Garriga J, Price DH, Graña X, Peterlin BM. The ability of positive transcription elongation factor B to transactivate human immunodeficiency virus transcription depends on a functional kinase domain, cyclin T1, and Tat. J Virol. 1998 Sep; 72(9):7154-9.
  78. Lu X, Yu H, Liu SH, Brodsky FM, Peterlin BM. Interactions between HIV1 Nef and vacuolar ATPase facilitate the internalization of CD4. Immunity. 1998 May; 8(5):647-56.
  79. Luo W, Peterlin BM. Activation of the T-cell receptor signaling pathway by Nef from an aggressive strain of simian immunodeficiency virus. J Virol. 1997 Dec; 71(12):9531-7.
  80. Cujec TP, Okamoto H, Fujinaga K, Meyer J, Chamberlin H, Morgan DO, Peterlin BM. The HIV transactivator TAT binds to the CDK-activating kinase and activates the phosphorylation of the carboxy-terminal domain of RNA polymerase II. Genes Dev. 1997 Oct 15; 11(20):2645-57.
  81. Fontes JD, Jabrane-Ferrat N, Peterlin BM. Assembly of functional regulatory complexes on MHC class II promoters in vivo. J Mol Biol. 1997 Jul 18; 270(3):336-45.
  82. Fontes JD, Jiang B, Peterlin BM. The class II trans-activator CIITA interacts with the TBP-associated factor TAFII32. Nucleic Acids Res. 1997 Jun 15; 25(12):2522-8.
  83. Cujec TP, Cho H, Maldonado E, Meyer J, Reinberg D, Peterlin BM. The human immunodeficiency virus transactivator Tat interacts with the RNA polymerase II holoenzyme. Mol Cell Biol. 1997 Apr; 17(4):1817-23.
  84. Lim CS, Jabrane-Ferrat N, Fontes JD, Okamoto H, Garovoy MR, Peterlin BM, Hunt CA. Sequence-independent inhibition of RNA transcription by DNA dumbbells and other decoys. Nucleic Acids Res. 1997 Feb 1; 25(3):575-81.
  85. Lu X, Wu X, Plemenitas A, Yu H, Sawai ET, Abo A, Peterlin BM. CDC42 and Rac1 are implicated in the activation of the Nef-associated kinase and replication of HIV-1. Curr Biol. 1996 Dec 1; 6(12):1677-84.
  86. Okamoto H, Sheline CT, Corden JL, Jones KA, Peterlin BM. Trans-activation by human immunodeficiency virus Tat protein requires the C-terminal domain of RNA polymerase II. Proc Natl Acad Sci U S A. 1996 Oct 15; 93(21):11575-9.
  87. Jabrane-Ferrat N, Fontes JD, Boss JM, Peterlin BM. Complex architecture of major histocompatibility complex class II promoters: reiterated motifs and conserved protein-protein interactions. Mol Cell Biol. 1996 Sep; 16(9):4683-90.
  88. Fontes JD, Jabrane-Ferrat N, Toth CR, Peterlin BM. Binding and cooperative interactions between two B cell-specific transcriptional coactivators. J Exp Med. 1996 Jun 1; 183(6):2517-21.
  89. Sawai ET, Baur AS, Peterlin BM, Levy JA, Cheng-Mayer C. A conserved domain and membrane targeting of Nef from HIV and SIV are required for association with a cellular serine kinase activity. J Biol Chem. 1995 Jun 23; 270(25):15307-14.
  90. Jabrane-Ferrat N, Peterlin BM. Ets-1 activates the DRA promoter in B cells. Mol Cell Biol. 1994 Nov; 14(11):7314-21.
  91. Alonso A, Cujec TP, Peterlin BM. Effects of human chromosome 12 on interactions between Tat and TAR of human immunodeficiency virus type 1. J Virol. 1994 Oct; 68(10):6505-13.
  92. Mujeeb A, Bishop K, Peterlin BM, Turck C, Parslow TG, James TL. NMR structure of a biologically active peptide containing the RNA-binding domain of human immunodeficiency virus type 1 Tat. Proc Natl Acad Sci U S A. 1994 Aug 16; 91(17):8248-52.
  93. Adams M, Sharmeen L, Kimpton J, Romeo JM, Garcia JV, Peterlin BM, Groudine M, Emerman M. Cellular latency in human immunodeficiency virus-infected individuals with high CD4 levels can be detected by the presence of promoter-proximal transcripts. Proc Natl Acad Sci U S A. 1994 Apr 26; 91(9):3862-6.
  94. Sawai ET, Baur A, Struble H, Peterlin BM, Levy JA, Cheng-Mayer C. Human immunodeficiency virus type 1 Nef associates with a cellular serine kinase in T lymphocytes. Proc Natl Acad Sci U S A. 1994 Feb 15; 91(4):1539-43.
  95. Baur A, Garber S, Peterlin BM. Effects of CD45 on NF-kappa B. Implications for replication of HIV-1. J Immunol. 1994 Feb 1; 152(3):976-83.
  96. Ghosh S, Selby MJ, Peterlin BM. Synergism between Tat and VP16 in trans-activation of HIV-1 LTR. J Mol Biol. 1993 Dec 5; 234(3):610-9.
  97. Luo Y, Madore SJ, Parslow TG, Cullen BR, Peterlin BM. Functional analysis of interactions between Tat and the trans-activation response element of human immunodeficiency virus type 1 in cells. J Virol. 1993 Sep; 67(9):5617-22.
  98. Tong-Starksen SE, Baur A, Lu XB, Peck E, Peterlin BM. Second exon of Tat of HIV-2 is required for optimal trans-activation of HIV-1 and HIV-2 LTRs. Virology. 1993 Aug; 195(2):826-30.
  99. Luo Y, Peterlin BM. Juxtaposition between activation and basic domains of human immunodeficiency virus type 1 Tat is required for optimal interactions between Tat and TAR. J Virol. 1993 Jun; 67(6):3441-5.
  100. Voliva CF, Tsang S, Peterlin BM. Mapping cis-acting defects in promoters of transcriptionally silent DQA2, DQB2, and DOB genes. Proc Natl Acad Sci U S A. 1993 Apr 15; 90(8):3408-12.
  101. Lu X, Welsh TM, Peterlin BM. The human immunodeficiency virus type 1 long terminal repeat specifies two different transcription complexes, only one of which is regulated by Tat. J Virol. 1993 Apr; 67(4):1752-60.
  102. Alonso A, Derse D, Peterlin BM. Human chromosome 12 is required for optimal interactions between Tat and TAR of human immunodeficiency virus type 1 in rodent cells. J Virol. 1992 Jul; 66(7):4617-21.
  103. Voliva CF, Aronheim A, Walker MD, Peterlin BM. B-cell factor 1 is required for optimal expression of the DRA promoter in B cells. Mol Cell Biol. 1992 May; 12(5):2383-90.
  104. Peterlin BM. Transcriptional regulation of HLA-DRA gene. Res Immunol. 1991 Jun-Aug; 142(5-6):393-9.
  105. Chin DJ, Selby MJ, Peterlin BM. Human immunodeficiency virus type 1 Tat does not transactivate mature trans-acting responsive region RNA species in the nucleus or cytoplasm of primate cells. J Virol. 1991 Apr; 65(4):1758-64.
  106. Tong-Starksen SE, Welsh TM, Peterlin BM. Differences in transcriptional enhancers of HIV-1 and HIV-2. Response to T cell activation signals. J Immunol. 1990 Dec 15; 145(12):4348-54.
  107. Andersson G, Peterlin BM. NF-X2 that binds to the DRA X2-box is activator protein 1. Expression cloning of c-Jun. J Immunol. 1990 Nov 15; 145(10):3456-62.
  108. Selby MJ, Peterlin BM. Trans-activation by HIV-1 Tat via a heterologous RNA binding protein. Cell. 1990 Aug 24; 62(4):769-76.
  109. Tsang SY, Nakanishi M, Peterlin BM. Mutational analysis of the DRA promoter: cis-acting sequences and trans-acting factors. Mol Cell Biol. 1990 Feb; 10(2):711-9.
  110. Peterlin BM, Andersson G, Lötscher E, Tsang S. Transcriptional regulation of HLA class-II genes. Immunol Res. 1990; 9(3):164-77.
  111. Seto E, Zhou DX, Peterlin BM, Yen TS. trans-activation by the hepatitis B virus X protein shows cell-type specificity. Virology. 1989 Dec; 173(2):764-6.
  112. Selby MJ, Bain ES, Luciw PA, Peterlin BM. Structure, sequence, and position of the stem-loop in tar determine transcriptional elongation by tat through the HIV-1 long terminal repeat. Genes Dev. 1989 Apr; 3(4):547-58.
  113. Calman AF, Peterlin BM. Evidence for a trans-acting factor that regulates the transcription of class II major histocompatibility complex genes: genetic and functional analysis. Proc Natl Acad Sci U S A. 1988 Dec; 85(23):8830-4.
  114. Seto E, Yen TS, Peterlin BM, Ou JH. Trans-activation of the human immunodeficiency virus long terminal repeat by the hepatitis B virus X protein. Proc Natl Acad Sci U S A. 1988 Nov; 85(21):8286-90.
  115. Tsang SY, Nakanishi M, Peterlin BM. B-cell-specific and interferon-gamma-inducible regulation of the HLA-DR alpha gene. Proc Natl Acad Sci U S A. 1988 Nov; 85(22):8598-602.
  116. Calman AF, Busch MP, Vyas GN, McHugh TM, Stites DP, Peterlin BM. Transcription and replication of human immunodeficiency virus-1 in B lymphocytes in vitro. AIDS. 1988 Jun; 2(3):185-93.
  117. Peltz G, Frederick K, Anderson CL, Peterlin BM. Characterization of the human monocyte high affinity Fc receptor (hu FcRI). Mol Immunol. 1988 Mar; 25(3):243-50.
  118. Peterlin BM, Luciw PA. Molecular biology of HIV. AIDS. 1988; 2 Suppl 1:S29-40.
  119. Peltz GA, Gallis B, Peterlin BM. Monoclonal antibody immunoprecipitation of cell membrane glycoproteins. Anal Biochem. 1987 Dec; 167(2):239-44.
  120. Kao SY, Calman AF, Luciw PA, Peterlin BM. Anti-termination of transcription within the long terminal repeat of HIV-1 by tat gene product. Nature. 1987 Dec 3-9; 330(6147):489-93.
  121. Calman AF, Peterlin BM. Mutant human B cell lines deficient in class II major histocompatibility complex transcription. J Immunol. 1987 Oct 1; 139(7):2489-95.
  122. Tong-Starksen SE, Luciw PA, Peterlin BM. Human immunodeficiency virus long terminal repeat responds to T-cell activation signals. Proc Natl Acad Sci U S A. 1987 Oct; 84(19):6845-9.
  123. Sullivan KE, Peterlin BM. Transcriptional enhancers in the HLA-DQ subregion. Mol Cell Biol. 1987 Sep; 7(9):3315-9.